Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?

Rył, Aleksandra; Rotter, Iwona; Miazgowski, Tomasz; Słojewski, Marcin; Dołęgowska, Barbara; Lubkowska, Anna

doi:10.1186/s13098-015-0089-1

Cited by 32 publications

(30 citation statements)

References 37 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…et al, 2016). Estrogen induced stimulation of prostatic growth has also been reported in dogs and monkeys (Jeyaraj et al, 2000; Roehrborn and McConnell, 2002; Aleksandra et al, 2015). …”

Section: Etiology Of Bphmentioning

confidence: 81%

“…Aging has been implicated as the major risk factor for the development of BPH (Roehrborn and McConnell, 2002; Aleksandra et al, 2015). Several studies have demonstrated a relationship between age and markers of BPH progression (Neuhouser et al, 2008; Liu et al, 2009).…”

Section: Etiology Of Bphmentioning

confidence: 99%

“…Testosterone is converted to DHT by the intracellular enzyme, 5α reductase type 2 (Roehrborn and McConnell, 2002; Alberto et al, 2009; Aleksandra et al, 2015) which is located on the prostatic nuclear membrane for both the stroma and the epithelium (Roehrborn and McConnell, 2002; Aleksandra et al, 2015). …”

Section: Etiology Of Bphmentioning

confidence: 99%

“…It usually begins as a simple micronodular hyperplasia with a subsequent macroscopic nodular enlargement that may result in bladder outlet obstruction and the development of lower urinary tract symptoms (LUTS) (Aleksandra et al, 2015). …”

Section: Introductionmentioning

confidence: 99%

“…Although the molecular and stromal mechanisms associated with the pathogenesis of this metabolic disorder have not yet been fully elucidated (Aleksandra et al, 2015), several factors such as: inflammatory mediators, hormonal, dietary factors, environmental and oxidative stress have been implicated in its etiology (Minciullo et al, 2015). …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Eleazu¹,

Eleazu

Kalu

2017

Front. Pharmacol.

View full text Add to dashboard Cite

The incidence of benign prostatic hyperplasia (BPH) is gradually on the increase. While conventional drugs such as the α1-adrenergic receptor antagonists and 5α-reductase inhibitors have been found to be useful in the treatment of BPH, the adverse side effects associated with their usage, have led to increased search for alternative means of managing this disease. Furthermore, although surgery has also been suggested to be a sure method, the cost and risks associated with it excludes it as a routine treatment. Dietary polyphenols have gained public interest in recent times due to their roles in the prevention of various diseases that implicate free radicals/reactive oxygen species. However, their roles in the management of BPH have not been explored. Hence, this review on their prospects in the management of BPH and their mechanisms of action. Literature search was carried out in several electronic data bases such as PubMed, Google Scholar, Medline, Agora, and Hinari from1970 to 2017 to identify the current status of knowledge on this concept. The findings from these data bases suggest that while dietary polyphenols may not replace the need for the existing therapies in the management of BPH, they hold promise in BPH management which could be explored by researchers working in this field.

show abstract

“…et al, 2016). Estrogen induced stimulation of prostatic growth has also been reported in dogs and monkeys (Jeyaraj et al, 2000; Roehrborn and McConnell, 2002; Aleksandra et al, 2015). …”

Section: Etiology Of Bphmentioning

confidence: 81%